Literature DB >> 8737779

Interleukin 1 (IL-1) and IL-1-receptor antagonist (IL-1-RA) in middle ear cholesteatoma: an analysis of protein production and biological activity.

J Bujía1, C Kim, P Ostos, H Sudhoff, E Kastenbauer, L Hültner.   

Abstract

Cytokine networks are now presumed to play an essential role in the pathogenesis of middle ear cholesteatoma. Of the factors identified in cholesteatoma, interleukin-I (IL-1)-alpha appears to be especially important because of its stimulation of keratinocyte proliferation as well induction of bone resorption. To further characterize the possible role of IL-1 in the pathogenesis of cholesteatoma, we quantified the levels of IL-1 and IL-1-receptor antagonist (IL-1-RA) present using the bicinchonic acid protein assay and enzyme-linked immunosorbent assay (ELISA) on tissue extracts from 20 cholesteatoma specimens. The presence of biologically active IL-1 was also analyzed, using the cell line LBRM-33 and an ELISA for the detection of interleukin-2 (IL-2). Human skin obtained from the external ear canal was used as control. The amounts of IL-1-alpha in cholesteatoma (34.9 +/- 19.5) were higher than in human skin (6.7 +/- 2.8). The observed differences were statistically significant by Student's t-test (P < 0.01). Skin samples showed elevated concentrations of IL-1-RA (248.3 +/- 30.2) in comparison to that in the cholesteatoma (80.8 +/- 13.5). This was also statistically significant (P < 0.01). Whereas IL-1 activity was not detected in skin samples, all cholesteatoma specimens studied showed a stimulation effect on the production of IL-2 when incubated with the cell line LBRM-33. The results point to an over-expression of IL-1 concurrent with a decreased secretion of IL-1-RA in middle ear cholesteatoma. Furthermore IL-1-RA production is deficient relative to total IL-1 production, resulting in the presence of active IL-1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8737779     DOI: 10.1007/bf00171137

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  26 in total

1.  Quantitative analysis of cytokine gene expression in rheumatoid arthritis.

Authors:  G S Firestein; J M Alvaro-Gracia; R Maki; J M Alvaro-Garcia
Journal:  J Immunol       Date:  1990-05-01       Impact factor: 5.422

2.  cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium.

Authors:  S Haskill; G Martin; L Van Le; J Morris; A Peace; C F Bigler; G J Jaffe; C Hammerberg; S A Sporn; S Fong
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

3.  Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production.

Authors:  P Seckinger; J Klein-Nulend; C Alander; R C Thompson; J M Dayer; L G Raisz
Journal:  J Immunol       Date:  1990-12-15       Impact factor: 5.422

4.  Lymphotoxin in human middle ear cholesteatoma.

Authors:  S D Yan; C C Huang
Journal:  Laryngoscope       Date:  1991-04       Impact factor: 3.325

5.  Antagonistic and agonistic effects of transforming growth factor-beta and IL-1 in rheumatoid synovium.

Authors:  S M Wahl; J B Allen; H L Wong; S F Dougherty; L R Ellingsworth
Journal:  J Immunol       Date:  1990-10-15       Impact factor: 5.422

6.  Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s).

Authors:  J F Balavoine; B de Rochemonteix; K Williamson; P Seckinger; A Cruchaud; J M Dayer
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

7.  Third place--Resident Basic Science Award 1990. Interleukin 1 causing bone destruction in middle ear cholesteatoma.

Authors:  J M Ahn; C C Huang; M Abramson
Journal:  Otolaryngol Head Neck Surg       Date:  1990-10       Impact factor: 3.497

8.  Possible autocrine growth stimulation of cholesteatoma epithelium by transforming growth factor alpha.

Authors:  P Schulz; J Bujía; A Holly; V Shilling; E Kastenbauer
Journal:  Am J Otolaryngol       Date:  1993 Mar-Apr       Impact factor: 1.808

9.  IL-1 receptor antagonist and IL-1 beta production in human monocytes are regulated differently.

Authors:  W P Arend; M F Smith; R W Janson; F G Joslin
Journal:  J Immunol       Date:  1991-09-01       Impact factor: 5.422

Review 10.  Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro.

Authors:  C A Dinarello; R C Thompson
Journal:  Immunol Today       Date:  1991-11
View more
  4 in total

Review 1.  Etiopathogenesis of cholesteatoma.

Authors:  Ewa Olszewska; Mathias Wagner; Manuel Bernal-Sprekelsen; Jörg Ebmeyer; Stefan Dazert; Henning Hildmann; Holger Sudhoff
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-06-27       Impact factor: 2.503

2.  Cholesteatoma growth and proliferation: posttranscriptional regulation by microRNA-21.

Authors:  David R Friedland; Rebecca Eernisse; Christy Erbe; Nidhi Gupta; Joseph A Cioffi
Journal:  Otol Neurotol       Date:  2009-10       Impact factor: 2.311

3.  Increased Acquired Cholesteatoma Risk in Patients with Osteoporosis: A Retrospective Cohort Study.

Authors:  Tang-Chuan Wang; Che-Chen Lin; Chia-Der Lin; Hsiung-Kwang Chung; Ching-Yuang Wang; Ming-Hsui Tsai; Chia-Hung Kao
Journal:  PLoS One       Date:  2015-07-14       Impact factor: 3.240

Review 4.  Review of potential medical treatments for middle ear cholesteatoma.

Authors:  Matthias Schürmann; Peter Goon; Holger Sudhoff
Journal:  Cell Commun Signal       Date:  2022-09-19       Impact factor: 7.525

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.